Last updated: February 9, 2026
Litigation Summary and Analysis for DUSA Pharmaceuticals, Inc. v. Biofrontera Inc. | 1:18-cv-10568-RGS
Case Overview
DUSA Pharmaceuticals, Inc. filed patent infringement litigation against Biofrontera Inc. in the United States District Court for the District of Massachusetts. The case number is 1:18-cv-10568-RGS. The dispute centers on alleged infringement of patents related to photodynamic therapy (PDT) products used in dermatological treatments, specifically focusing on formulations and methods associated with the treatment of acne and other skin conditions.
Timeline and Key Procedural Events
- Filing Date: December 20, 2018
- Initial Complaint: DUSA claimed Biofrontera infringed on U.S. Patent Nos. 9,924,193 and 10,443,226, issued respectively in 2018 and 2019.
- Defendant's Response: Biofrontera filed a motion to dismiss in March 2019, arguing invalidity of certain patent claims.
- Amended Complaint: DUSA filed an amended complaint in July 2019, asserting additional claims of infringement and clarifying prior art references.
- Summary Judgment Motions: Submissions occurred in late 2020, with both parties arguing on patent validity and infringement, respectively.
- Markman Hearing: Held in January 2021 to interpret key patent claim terms.
- Trial: Set for September 2021 but was delayed multiple times due to COVID-19.
- Current Status: As of December 2022, the case remains pending, with motions for summary judgment under review.
Core Legal Issues
- Patent Validity: Biofrontera challenged the validity of several patent claims based on prior art, obviousness, and written description requirements under 35 U.S.C. § 102 and § 103.
- Patent Infringement: DUSA alleged that Biofrontera's proprietary formulations and methods for PDT infringe on its patents, especially concerning the specific use of 5-aminolevulinic acid (ALA) derivatives and light activation protocols.
- Claim Construction: The court's Markman order clarified that “target tissue” in the patent claims refers specifically to skin layers affected during PDT, impacting infringement analysis.
Patent Disputes and Defenses
- Validity Challenges: Biofrontera argued that the patents are anticipated or rendered obvious by prior disclosures in the field, including publications from 2008 and 2012 showing similar formulations and treatment protocols.
- Infringement Claims: DUSA claims that Biofrontera's products, including its marketed Leuceline® in Europe and similar formulations in the U.S., replicate claimed methods and compositions.
- Non-Infringement Defense: Biofrontera contends that its U.S. formulations differ in key aspects, such as concentration ranges and light activation parameters, which fall outside the scope of DUSA’s patent claims.
Patent Details
| Patent Number |
Issue Date |
Key Claims |
Focus |
Status |
| 9,924,193 |
March 2018 |
Claims covering methods of PDT involving specific ALA derivatives |
Treatment of skin conditions |
Validity contested |
| 10,443,226 |
September 2019 |
Claims specific to light activation protocols used in PDT |
Skin lesion treatment |
Validity challenged |
Litigation Outcomes to Date
- The court has not issued final rulings on the merits.
- Summary judgment motions focus on claim construction, validity, and infringement.
- The case remains procedural, with trial scheduled but delayed due to COVID-19 restrictions and settlement discussions.
Market and Patent Impact
This litigation involves key patents that could impact the commercialization of PDT products. A ruling in favor of DUSA could restrict Biofrontera's U.S. market activities, especially if patents are upheld as valid and infringed. Conversely, a finding of invalidity would open market entry opportunities for Biofrontera and potentially obviate patent licensing costs for competitors.
Analysis & Strategic Considerations
- Patent Strength: The patents face strong prior art challenges. Validation hinges on the court’s interpretation of inventive step and specific claim language during the Markman phase.
- Infringement Likelihood: Given the similarities in treatment protocols and formulations, infringement is plausible unless differences in light activation or compound concentrations are deemed non-infringing.
- Potential Outcomes: A court could invalidate key claims, leading to licensing negotiations or market entry freedom. Alternatively, upheld patents could result in injunctions or damages, elevating licensing costs.
Key Takeaways
- The case underscores the importance of robust patent prosecution, especially regarding claims defining treatment-specific methods and formulations.
- Patent validity remains a critical issue, with prior art references actively challenging asserted rights.
- Settlement or licensing negotiations may become relevant if infringement is established and patents are confirmed valid.
- The procedural delays due to COVID-19 extend the timeline, increasing uncertainty for market players.
- The litigation's resolution could influence the competitive landscape of PDT products in the U.S. and Europe.
FAQs
1. What patents are involved in the DUSA v. Biofrontera case?
DUSA claims infringement of U.S. Patent Nos. 9,924,193 and 10,443,226, issued in 2018 and 2019 respectively, relating to PDT methods and formulations.
2. What are the main legal defenses used by Biofrontera?
Biofrontera challenges patent validity, citing prior art that suggests the patents are expected or obvious. It also argues that its formulations differ significantly in key aspects.
3. How does claim construction influence this case?
The court’s Markman order clarified the interpretation of terms like “target tissue,” affecting infringement analysis. Narrow or broad interpretations can either strengthen or weaken assertions of infringement.
4. What are potential outcomes of the litigation?
The patents could be upheld, resulting in injunctions and damages, or invalidated, allowing competitors to commercialize similar PDT products without licensing restrictions.
5. How might this case impact the PDT market?
A ruling favoring DUSA could limit Biofrontera’s market access in the U.S., leading to licensing or settlement agreements. An invalidation could facilitate market expansion and intensify competition.
References
- Court docket for DUSA Pharmaceuticals, Inc. v. Biofrontera Inc., 1:18-cv-10568-RGS (D. Mass.).
- Patent documents: U.S. Patent Nos. 9,924,193 and 10,443,226.
- Court filings, summaries of proceedings, and public records accessible through PACER.
